

# Grape King Bio (1707 TT/TW) Investor Presentation Feb 13, 2025

Confidential

#### **Geometry Company Milestones**





# FY24 Revenue & 1Q-3Q24 Results

Confidentia

## Company Overview : Three core business units

#### 1. Taiwan Grape King (Parent Co)

#### Taiwan own brand & global OEM & ODM

Focus of all key ingredient design, formulation, and production for the whole Group.


#### 2. Pro-Partner (60%-own)

#### Taiwan direct selling distribution


A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.

#### **3. Shanghai Grape King** (100%-own) China OEM & ODM

*Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.* 



## **FY24 Revenue Up 4.9%**



FY24 Revenue Growth +524M (Shanghai Grape King: +328M · Pro-Partner +264M · Taiwan -68M)

#### 2024 1Q-3Q EPS Surpasses Last Year

Cumulative EPS (NT\$)

	1Q	1Q-2Q	1Q-3Q	1Q-4Q
2021	1.60	3.8	5.84	8.82
2022	1.59	4.19	6.65	9.83
2023	1.89	4.17	6.65	9.81
2024	1.74	3.95	6.76	

4Q24 revenue slightly declined year-over-year as Pro-Partner members stocked up early in September due to price adjustments. H1/H2 Profit is proportionate to revenue to some extent.

#### **Income Statement**

(NT\$ mn)	2019	2020	2021	2022	2023
Revenue	9,239	9,168	9,798	10,391	10,635
Gross Profit	7,566	7,537	7,855	8,481	8,534
Operating Expenses	(5,231)	(5,232)	(5,543)	(5,929)	(6,037)
Operating Profit	2,335	2,305	2,312	2,552	2,497
Non Operating Income/(Loss)	105	73	103	136	164
Pretax Income	2,440	2,378	2,415	2,688	2,661
Tax Expenses	(502)	(483)	(467)	(518)	(519)
Minority Interest	(630)	(623)	(647)	(713)	(689)
Net income to Parent	1,309	1,272	1,300	1,457	1,453
Basic EPS (NT\$)	9.63	9.34	8.81	9.84	9.81
1H EPS as % of FY EPS	44%	43%	43%	43%	43%
Key Financial Ratios (%)					
Gross Margin	81.9	82.2	80.2	81.6	80.2
Operating Expense Ratio	56.6	57.1	56.6	57.1	56.8
Operating Margin	25.3	25.1	23.6	24.6	23.5
Effective Tax Rate	20.6	20.3	19.3	19.3	19.5
Net Margin	14.2	13.9	19.9	20.9	20.1

1Q-3Q23	1Q-3Q24	YoY(%)
7,435	8,005	7.7%
5,981	6,185	3.4%
-4,307	-4,450	3.3%
1,674	1,735	3.6%
124	118	-4.8%
1,798	1,853	3.1%
-356	-353	-0.8%
-458	-498	8.7%
984	1,002	1.8%
6.65	6.76	1.7%
80.4	77.3	
57.9	55.6	
22.5	21.7	
19.8	19.1	
19.4	18.7	

## Dividend Payout and Capex

(NT\$ mn)	2019	2020	2021	2022	2023	2024
Net Profit	1,309	1,272	1,300	1,457	1,453	
Cash Dividend	884	948	904	1,022	1,022	
Cash DPS (NT\$)	6.5	6.4	6.1	6.9	6.9	To Be Announced
Payout Ratio	67.4%	68.5%	69.2%	70.1%	70.3%	
EPS (NT\$)	9.63	9.34	8.81	9.84 (*1)	9.81	
Сарех	630	1,214	1,481	1,005 (*2)	1,078(*3)	504 (*4)

Notes(\*):

- 1. Grape King decided to apply for rights issue of 11,851,000 shares through a private placement for Uni-President (1216 TT) to become a shareholder and strategic partner on January 14th, 2021.
- 2. Capex of 2021 and 2022 include: factory and equipment for the first phase of Yongfeng Plant in Pingzhen.
- 3. Capex of 2023 include: factory and equipment for Longtan Plant Phase II, new soft capsule production line, new jelly gel production line, and PIC/S line expansion.
- 4. The phase I of Yongfeng Plant in Pingzhen and the phase II Longtan Plant are on-going projects from 2023, relevant Capex highlighted in 2022 and 2023.

## **Galance Sheet**

(NT\$ mn)	2019	2020	2021	2022	2023	1Q-3Q24
Total Assets	11,359	13,104	14,061	15,053	15,512	14,406
Cash	2,146	2,927	3,635	4,673	4,819	3,294
AR & NR	202	202	301	270	291	285
Inventories	546	689	719	688	688	810
Fixed Assets	6,454	7,308	7,208	7,360	7,539	7,745
Total Liabilities	3,888	5,126	3,632	3,912	3,882	2,875
AP & NP	223	255	269	294	290	379
Total Borrowings	1,177	1,921	94	0	0	0
Total Equity	7,471	7,978	10,429	11,141	11,630	11,531
Key Financial Ratios (%)						
A/R turnover days	7.3	7.9	9.5	10.1	9.7	9.8
Inv turnover days	119.3	136.4	135.2	139.8	124.6	112.7
A/P turnover days	52.2	52.7	49.3	53.8	50.7	50.7
Cash conversion cycle	74.4	91.6	95.4	96.1	83.6	71.8
ROE (%)	26.9	24.5	21.2	20.1	18.8	19.0
ROA (%)	17.6	15.5	14.3	14.9	14.0	15.0
Net Debt to Equity (%)	(13.0)	(12.6)	(34.0)	(41.9)	(41.4)	(28.6)

#### \*Key Financial Ratios for 1Q-3Q24 Expressed on an Annualized Basis


## **Gamma Statement**

(NT\$ mn)	3Q23	3Q24	YoY(%)
Revenue	2,551	2,899	13.7%
Gross Profit	2,009	2,265	12.6%
Operating Expenses	(1,375)	(1,518)	10.4%
Operating Profit	634	747	17.8%
Non Operating Income/(Loss)	47	30	-36.8%
Pretax Income	681	777	14.0%
Tax Expenses	(134)	(153)	13.6%
Minority Interest	(180)	(208)	15.4%
Net income to Parent	367	416	13.5%
Basic EPS (NT\$)	2.48	2.81	13.3%
Key Financial Ratios (%)			
Gross Margin	78.8	78.1	
Operating Expense Ratio	53.9	52.4	
Operating Margin	24.9	25.8	
Effective Tax Rate	19.7	19.7	
Net Margin	21.4	21.5	

# 1. Taiwan Grape King

"


#### **Grape King Taiwan - Business Overview**




#### Grape King Taiwan – Own Brand Business Overview



## Grape King Taiwan – ODM/OEM Business Overview



#### Grape King Taiwan -2024 ODM/OEM Performance



\*PIC/S halted production in the first half of 2024 due to material shortages, but normal shipments have resumed as of July.

#### **66** Botanical Drug Has Entered the 2nd Phase of Testing by the USFDA

- Antrodia is a traditional Chinese mushroom unique to Taiwan, often referred to as the "Forest Ruby." It is renowned for its liver-protective properties and cancer-fighting benefits.
- Grape King Bio has dedicated over 20 years to researching Antrodia, completing numerous efficacy studies and securing patents, which positions us as the leading brand in Taiwan.
- We have developed a new botanical medicine, GKAC, targeting non-alcoholic fatty liver disease (NAFLD). Currently, it is in Phase II clinical trials with the US FDA.
- According to a forecast by Report Ocean, the global NAFLD drug market is projected to reach \$21.5 billion by 2025, growing at a compound annual growth rate (CAGR) of 58.4%.
- Grape King Bio's Antrodia extract is shown to improve liver function and prevent cirrhosis and liver cancer in patients with NAFLD. Our goal is to be the first company to introduce a plant-based NAFLD drug following US FDA approval.
- Current progress:
  - (1) Undergoing GLP animal testing (rats & beagles).
  - (2) Next step: Human clinical trials.



"

#### Pro-Partner Overview - 4 Key Numbers



(Based on Revenue Rankings)




(2023 Market Share: 9.36%)



#### Ranked 38th in the

World Direct Sales Rankings for 2024 (Source: 2024 DSN Global 100-Based on Revenue Rankings for 2023) 47 products, including health supplements, skincare solutions &oral care essentials.



## **Gepening Our Roots in Taiwan, Expanding Globally**

- Pro-Partner is gearing up to expand into international markets, starting with Malaysia, which has a robust direct sales industry.
- We are currently planning 20 products, of which 5 have already been submitted for MAL certification.
- We expect to launch global market sales in 2025.



葡衆企業 PRO-PARTNER




# 3. Shanghai Grape King

"



#### **Integrated OEM Services Platform**



- \* Note: Drop Shipping
- 1. Commencing in June 2024
- 2. Offering services to enhance OEM opportunities
- 3. Maximizing the utilization of available warehouse space



"

## Customers of Shanghai Grape King



## <sup>44</sup> Own Brands of Shanghai Grape King





牛磺酸 · 维生素 B1 · 维生素 B1 · 速溶红茶 · 长白山人参粉 运动随时GO /

#### **ComeBest Ginseng Vitamin Drinksl.**

1) Distribution Points: Gas stations, Chess rooms, Logistics

centers, Harbors, 7-Eleven, Vending machines\*, etc.

- 2) Revenue Generation: Launched in 7-Eleven in 2Q24.
- **3) Strategy:** Focus on selling fast-moving products through our own distribution channels.
- \* Vending Machine Business:
- Launching in September.
- Increase brand visibility.
- Enter the unmanned retail market in China.



# **Plans and Strategies**

Confidential

## **Gutlooks**

- Shanghai Grape King :
  - ODM / OEM ∶ The liquid production line expands to incorporate a carbonated beverage dosage form → Expand the fast-moving consumer goods (FMCG) sector
  - Channel Resource Integration :
    - PuJun Expand the traditional distribution channel and introduce own brand products
    - PuYou Expand the vending machine channel and develop own brand products (Central China)
    - PuGuang Expand the vending machine channel and develop own brand products (Southern China)
    - PuXun Integrate clients' demands and implement direct shipment from the factory
    - PuBai Enter cross-border e-commerce and expand own brand products
- Taiwan Grape King :
  - Own brand : Launch new products (Super Fish Oil 369 Slim Probiotics EX Probiotics King EX)
  - ODM/OEM : Expand new dosages to increase the revenue
- Pro-Partner :
  - Launch new products





"

# Thank you!

#### For more information, please refer to our website. :

www.grapeking.com.tw